Larimar Therapeutics, Inc. (LRMR)


+0.11 (+2.69%)

Dr. Carole S. Ben-Maimon M.D.
NASDAQ Global Market

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.